# Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer

> **NCT03662035** · PHASE2 · UNKNOWN · sponsor: **Changzhou No.2 People's Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **DRUG:** Apatinib
- **DRUG:** S-1

## Key facts

- **NCT ID:** NCT03662035
- **Lead sponsor:** Changzhou No.2 People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-15
- **Primary completion:** 2020-03-01
- **Final completion:** 2020-08-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2018-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03662035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03662035, "Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03662035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*